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Background: Acute respiratory distress syndrome (ARDS) is the most common cause of respiratory failure among
critically ill patients. Novel treatment strategies are required to address this common clinical problem. The
application of exogenous adult stem cells was associated with a beneficial outcome in various pre-clinical models
of ARDS. In the present study we evaluated the functional capacity and homing ability of bone marrow-derived
progenitor cells (BMDPC) in vitro and investigated their potential as a treatment strategy in lipopolysaccharide
(LPS)-induced ARDS.
Results: Evaluation of the BMDPC showed functional capacity to form endothelial outgrowth cell colonies, which
stained positive for CD133 and CD31. Furthermore, DiI-stained BMDPC were demonstrated to home to injured lung
tissue. Rats treated with BMDPC showed significantly reduced histopathological changes, a reduced expression of
ICAM-1 and VCAM-1 by the lung tissue, an inhibition of proinflammatory cytokine synthesis, a reduced weight loss
and a reduced mortality (p < 0.03) compared to rats treated with LPS alone.
Conclusions: These findings suggest that the application of exogenous BMDPC can attenuate inflammation in
LPS-induced ARDS and thereby reduce the severity of septic organ damage. Cell therapy strategies using adult stem
cells might therefore become a novel and alternative option in ARDS therapy.
Keywords: Adult stem cells, Bone marrow-derived progenitor cells, Cell therapy, Acute respiratory distress
syndrome, LipopolysaccharideBackground
Acute respiratory distress syndrome (ARDS) is the most
common cause of respiratory failure among critically ill
patients. It commonly develops in patients with sepsis
and in this setting associates with high mortality [1]. Re-
gardless of the cause, the histologic changes of lung tissue
in the course of ARDS are characterized by infiltration
of inflammatory cells and destruction of pulmonary
endothelium [2,3] leading to increased pulmonary vas-
cular permeability and edema. Despite extensive re-
search and well-conducted clinical trials, no specific
novel treatment strategy exists to date [4,5] and existing* Correspondence: Grietje.Beck@hsk-wiesbaden.de
6Department for Anaesthesiology and Intensive Care Medicine, Dr.
Horst-Schmidt Clinic, Wiesbaden, Germany
Full list of author information is available at the end of the article
© 2014 Rafat et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.therapy is currently limited to supportive care [6,7]. A
novel potential treatment strategy for ARDS is the use of
bone marrow-derived progenitor cells (BMDPC) [8-11]. In
this regard, especially endothelial progenitor cells (EPC)
and mesenchymal stem cells have been shown to play a
role. An increased concentration of EPC was found in sep-
tic patients, which seem to be involved in pulmonary regen-
eration. The number of circulating EPC correlated inversely
to disease severity and mortality [12]. For a detailed over-
view on the role and effect of EPC in regeneration after
acute lung injury (ALI), please see [13]. While EPC initially
were thought to be recruited and incorporated into sites of
active neovascularization during e.g. tissue ischemia, vascu-
lar trauma, tumor growth and inflammation [14], more re-
cent work suggests different populations of endothelial
progenitor cells with distinct functions [13].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ducted to investigate the potential of mobilization or ad-
ministration of BMDPC in lung regeneration in different
lung disorders [13]. However, it is still unclear whether
progenitor cells can beneficially influence regeneration of
ARDS and which cell population should be used. We have
previously demonstrated that the application of BMDPC
in an endotoxin-induced ARDS rat model lead to an im-
proved gas exchange, an inhibition of proinflammatory
cytokine synthesis, an improved clinical course and a re-
duced mortality [15]. However, we have not looked at the
functional capacity of the administered BMDPC to prove
that they are responsible for the improved clinical course
and reduced mortality. Therefore in the present study, we
investigated in our isolated endotoxin-induced ARDS rat
model on one hand whether exogenically administered
bone marrow-derived CD133+ progenitor cells could bene-
ficially improve inflammation and survival. On the other
hand, we evaluated the functional capacity and homing
ability of the BMDPC, which were applied in our model.
Results
Animal model
The results of an extensive dose–response analysis revealed
reproducible lung damage with distinct clinical symptoms
consistent with moderate-to-severe ARDS at a LPS-
concentration of 25 μg/kg of body weight. The lungs of ani-
mals receiving LPS were infiltrated in large or disseminated
in small areas, to some extent livid discolorations and hem-
orrhages were visible (Figure 1A and 1B). Histopathologic-
ally, LPS-nebulization led to thickening of the alveolar wall
(Figure 1D and 1E) and an increased accumulation of
CD45 + −leucocytes (Figure 1G) compared to the control
group (Figure 1C and 1F). The number of animals in the
individual groups was as follows: control group: n = 9, treat-
ment group: n = 17, non-treatment group: n = 17.
Endothelial Outgrowth Cell (EOC) Assay
To test the functional capacity of the BMDPC, we seeded
the cells in culture flasks for 3 weeks. The cells showed a
good capacity to form endothelial outgrowth cell colonies
and proliferate to a high level of confluence (Figure 2A-C).
To verify their endothelial lineage, positive staining for
CD133 and CD31 showed that the cultured cells adopted
an endothelial character (Figure 2D and 2E).
BMDPC homing assay
To investigate whether the BMDPC are able to home to
injured lung tissue, BMDPC stained with DiI were ad-
ministered directly after LPS injection into the animals.
After forty-eight hours the animals were sacrificed and
their lung tissue analysed. Both in the alveolar tissue
(Figure 2F) and adhering to vascular wall (Figure 2G and
2H) fluorescent cells could be detected.Mortality
In the treatment group 13 out of 17 animals (76,5%) sur-
vived after 72 hours compared to 8 out of 17 animals
(47,1%) in the non-treatment group. Therefore, the
probability of survival of the animal in the treatment
group is significantly increased compared to the non-
treatment group (p < 0.03).
Clinical symptoms
For the evaluation of the disease course, we chose in this
study to observe the weight changes of the animals over
72 h. At the final time point the animals in the non-
treatment group showed a weight loss of 15% compared
to their initial weight, whereas the animals in the treat-
ment group only lost 11% of their initial weight.
Histopathologic data
Histopathologic evaluation revealed reduced interstitial
acute inflammation, inflammatory cellular infiltration and
thickening of the alveolar wall in the treatment group com-
pared to the non-treatment group (Figure 3A-C). Also, the
expression of the pro-inflammatory adhesion molecules
ICAM-1 (Figure 3D-F) and VCAM-1 (Figure 3G-I) were
significantly reduced in the treatment group compared to
the non-treatment group.
Bronchoalveolar Lavage (BAL)
Since inflammation triggers many cells to release VEGF,
we measured the concentration of VEGF in the bro-
choalveolar lavage (BAL) at the final time point. In the
treatment group VEGF was significantly decreased com-
pared to the non-treatment group (Figure 3J).
Wet/dry weight ratio
Pulmonary edema was analyzed by wet/dry weight ratio
(W/D Ratio) of the lungs at the final time point. While
the W/D Ratio in the control group was significantly de-
creased compared to the treatment and non-treatment
groups (Figure 3K), there was no significant statistical
difference between the treatment and the non-treatment
group (Figure 3K).
Discussion
Our findings demonstrated that exogenously administered
BMDPC can attenuate inflammation in LPS-induced
ARDS. Rats treated with BMDPC showed significantly re-
duced histopathological changes, a reduced expression of
ICAM-1 and VCAM-1 by the lung tissue and a reduced
concentration of proinflammatory VEGF in BAL. More-
over, the animal in the treatment group showed a reduced
weight loss and mortality compared to rats treated with
LPS alone. Evaluation of the BMDPC, which were applied
in this study, showed functional capacity to form endothe-
lial outgrowth cell colonies, which stained positive for






Figure 1 LPS-induced ARDS in a rat model. The macroscopic changes in lung seventy-two hours after lipopolysaccharide (LPS) nebulization
(B) and in control animals are displayed (A). The lungs of animals receiving LPS were infiltrated in large or disseminated in small areas, to some
extent livid discolorations and hemorrhages were visible. Lung tissue damage could also be determined immunhistochemically. While the control
group (C) showed intact lung tissue, LPS led to thickening of the alveolar wall (D, E) and an accumulation of inflammatory cells. CD45 staining
showed increased numbers of leucocytes in animals treated with LPS (G) compared to those undergoing a sham operation (F).
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homing of DiI-stained BMDPC to injured lung tissue, but
which was rather a seldom event. Previously, we have
already demonstrated that the application of BMDPC in
the same ARDS rat model lead to an improved gas ex-
change, an inhibition of proinflammatory cytokine synthe-
sis, an improved clinical course and a reduced mortality
[15]. However, we have not looked at the functional cap-
acity of the administered BMDPC to prove that they are
responsible for the improved clinical course and reduced
mortality. Therefore, with the present study, we have
added new insights into the therapeutic effects of BMDPC
in our ARDS model.
It is undisputed among researchers within the field that
BMDPC migrate to the location of revascularisation, initi-
ating proangiogenic effects via paracrine signalling or in
rather a small number differentiating directly to mature
endothelial or other cell types [13]. Increasing significance
is also attached to these progenitor cells with respect to
endothelial cell regeneration after acute and chronic
inflammation-induced tissue damage [16]. We and others
have demonstrated in previous studies that progenitor
cells are increasingly mobilized from the bone marrowinto the circulation during sepsis [12], ARDS [17] and
other inflammatory lung diseases [18].
The concentration of progenitor cells in the circulation
also correlated with the clinical outcome of the patients.
Based on this, a number of animal studies have been per-
formed to evaluate the effect of BMDPC mobilization or
administration in lung regeneration. Many of these studies
used an endotoxin-induced model of ALI/ARDS. We have
recently demonstrated that the application of BMDPC in
the same LPS-induced ARDS rat model lead to an im-
proved gas exchange, an inhibition of proinflammatory
cytokine synthesis, an improved clinical course and a re-
duced mortality [15]. For a detailed overview of the
in vitro-, clinical and animal studies looking at the role
and the therapeutic effect of BMDPC in ALI/ARDS, please
refer to [13].
In this present study, we examined on the one hand
whether the exogenic application of BMDPC has a bene-
ficial effect on the inflammation in experimental LPS-
induced ARDS and thereby on the clinical course. On
the other hand, we analysed whether the BMDPC popu-
lation applied in this study show functional capacity
in vitro and also home to the injured lung tissue.





Figure 2 Isolation, characterization and homing of bone marrow-derived progenitor cells (BMDPC). BMDPC were isolated from the bone
marrow cell suspension by positive selection for CD133 by microbeads associated with monoclonal anti-CD133-antibodies. To test their functional
capacity, the cells were seeded in culture flasks for 3 weeks. They were able to form endothelial outgrowth cell colonies quite early (A,B) and
proliferated to a high level of confluence (C) as seen via phase contrast microscopy. Staining for CD133 and CD31 showed that the cultured cells
adopted an endothelial character (D,E). To investigate the homing process, BMDPC were stained with DiI and administered directly after LPS injection
into the animals. After forty-eight hours the animals were sacrificed and their lung tissue analysed. Both in the alveolar tissue (F) and adhering to
vascular wall (G) fluorescent cells could be detected. In the cryosection (H) nuclei are stained with DAPI and one fluorescent could be detected.
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logical changes, a reduced expression of ICAM-1 and
VCAM-1 by the lung tissue, a reduced concentration of
VEGF in BAL, a reduced weight loss and mortality in ani-
mals which were treated with BMDPC after LPS nebuliza-
tion. Thus, the disease course was significantly improved.
In our vulnerable in vivo model, LPS was nebulized only
once to observe the acute phase of ARDS for seventy-two
hours. For long-time observations, multiple or permanent
applications of LPS will certainly have to be considered
and evaluated. In this study, the animals receiving LPS
only, who survived the acute stadium after seventy-two
hours, remained stable and reconstituted fully.
Our observations confirm previous results of animal
studies [19-24]. Gao et al. have demonstrated in a LPS-
induced ARDS rabbit model that systemic application of
progenitor cells inhibited the expression of adhesion mole-
cules and the synthesis of pro-inflammatory cytokines
(TNF-α or IL-1b) while significantly increasing the synthe-
sis of anti-inflammatory cytokines (IL-10) [25]. In our
study, we too observed a significantly reduced expression of
adhesion molecules following administration of BMDPC.
Interestingly, Gao et al. were also able to show a significant
reduction of the inflammation-induced apoptosis of endo-
thelial and epithelial cells by the application of progenitor
cells [25]. Based on these observations, it seems thatBMDPC not only stimulate vessel regeneration and repair
but also inhibit local inflammation [26]. In a recent study,
Rojas et al. have demonstrated a decrease of the severity
of LPS-induced ARDS in sheep by the instillation of
BMDPC [27]. Sheep treated with BMDPC showed rapid
recovery in oxygen levels, carbon dioxide clearance, pul-
monary vascular pressures and inflammation, confirmed
by histology and by the decrease in lung edema [27],
which we could not observe in our study. In another re-
cent study, Fan et al. showed that the application of EPC
and a SDF-1α analogue synergistically improved survival
in CLP-induced sepsis in a mice [28]. In accordance with
our observations, EPC-application resulted in decreased
lung vascular leakage and reduced inflammatory cell infil-
tration in the lung [28].
The mechanisms involved in the beneficial effects of
BMDPC/EPC are still unclear for the most part. Recruit-
ment and incorporation of BMDPC/EPC from bone
marrow into ischemic or injured tissue sites requires a
coordinated multistep process including mobilization,
chemotaxis, adhesion to the endothelium, transendothe-
lial migration, invasion and in situ differentiation [13].
The transdifferentiation of BMDPC/EPC into mature
endothelial cells is rather a rare event. Therefore, it was
not unexpected that we could only find a small number of
DiI-stained BMDPC homing to injured lung tissue In
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Figure 3 Bone marrow-derived progenitor cells (BMDPC) attenuate inflammation. Rats treated with BMDPC showed significantly improved
lung tissue using HE staining (C) compared to non-treatment group (B). Also, the expression of the proinflammatory adhesion molecules ICAM-1
(F) and VCAM-1 (I) were significantly reduced compared to the non-treatment group (E, H). A sham group served as a control group for all
stainings (A, D, G). In the bronchoalveolar lavage (BAL) VEGF was significantly increased in the non-treatment group compared to the treatment
and sham operation group (J). The W/D Ratio did not reveal any significant differences between the treatment and the non-treatment group,
while it was significantly lower in the sham group compared to the two other groups (K); *p < 0,05 (values displayed as mean) non-treatment
(LPS) versus treatment group (LPS + BMDPC).
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dothelial layer, release growth factors which stimulate an-
giogenic activity of resting mature endothelial cells [13].
This was also confirmed in a single-lung induced ARDS
model after intravenous BMDPC application [22]. BMDPC
homed exclusively to the lung with damaged endothelium,
but not to the contralateral healthy lung or to any other
healthy organ. Nonetheless, the experimental models were
not able to confirm an in vivo differentiation of BMDPC
into mature endothelial cells [22]. In our observations, we
could also show homing of BMDPC to injured lung tissue
and especially to the vessel wall. However, we looked only
into the in vitro differentiation of BMDPC into matureendothelial cells. In a different study, BMDPC did not inte-
grate into the vessel wall in ischemic models, but colonized
in subendothelial layers or on the surface of the endothe-
lium to induce their effects in a paracrine manner [29].
These paracrine effects consist of an increased release of
growth factors as well as chemokines and cytokines. Thus,
a proangiogenic environment is established, by which resi-
dent endothelial and other cell groups are stimulated to
proliferate [30].
First results on the potential significance of the BMDPC
surface molecules α4- or α5-integrin involved in the adhe-
sion of the endothelial matrix have been published [24]. In
an endotoxin-induced lung vascular injury and edema
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found in the damaged pulmonary tissue within twenty mi-
nutes. But the concentration of the BMDPC decreased by
40% over the next twenty-four hours. Furthermore, it was
also confirmed that adhesion of BMDPC to the tissue is
required to induce the BMDPC-triggered reduction of
vessel damage, oedema formation and mortality after LPS-
induced inflammation. The therapeutic effects of BMDPC
were not detectable anymore when the integrins were
blocked and by that adhesion of BMDPC diminished [24].
BMDPC/EPC are characterized and isolated by the
presence of trans-membrane glycoprotein CD133, which
is expressed as surface antigen on human progenitor
cells, but also on human hemangioblasts [31]. In con-
trast to the hematopoietic progenitor marker CD34,
CD133 is not expressed on mature endothelial cells, and
sub-populations of CD34+ cells, which also express
CD133, have a high proliferative capacity and lead to the
formation of endothelial colonies in cell culture [31]. We
also observed that CD133+/BMDPC had a high prolifera-
tive capacity and lead to the formation of endothelial col-
onies, which were also CD34+. Studies in animal models
report that circulating CD133+/BMDPC are involved in
the neoangiogenesis after tissue ischemia and in the regen-
eration of the damaged organ [32,33].
An increase of the BMDPC concentration in blood, as a
therapeutical option for severe inflammation with endothe-
lial damage in ARDS/ALI, may be induced in two manners.
First, an endogenic mobilization of EPC from the bone mar-
row can be stimulated by administration of growth factors,
such as VEGF, GM-CSF, EPO or SDF-1. By this means, an
effect could only be documented in a single cardiological
study [34,35] so far, and results from our own experimental
series in our LPS-induced isolated ARDS rat model are still
pending. Second, the exogenic application/transplantation
of BMDPC, as carried out in this study, seems to cause sig-
nificant effects in the inflammation model, but comprises
the disadvantage of requiring previous BMDPC prepar-
ation. In addition, differences in the treatment of local
vessel damage with “on-site application” as opposed to
treatment of generalized microvascular damage with sys-
temic BMDPC application have to be taken into account.
There are different limitations to this study. We have
used an isolated ARDS-model to investigate the role of
BMDPC. Patients suffering ARDS on intensive care units
are usually characterized by multi-morbidity, which has a
strong impact on their disease course and treatment. Also,
other factors affect the course of ARDS (e.g. different
mechanical ventilation protocols, differences in PEEP ap-
plication), which makes it difficult to transfer our findings
to the clinical setting. Furthermore, we have administered
BMDPC directly after LPS injection, which is not possible
in a clinical setting. By the time ARDS is present, there
might be no therapeutic effects of BMDPC anymore.Conclusions
In endotoxin-induced pulmonary endothelial dysfunction,
BMDPC seem to initiate repair mechanisms, which result
in a reduction of increased inflammation, permeability and
oedema formation, thus reducing mortality. Future studies
will have to analyse the underlying mechanisms involved in
this reparative process, so that BMDPC may become an in-
novative therapeutic strategy option in ARDS and sepsis.
Methods
Animal experiments
This study was approved by the Institutional Review Board
for the care of animal subjects (University of Heidelberg,
Mannheim, Germany & the Regional Council of Karlsruhe,
Germany). All animals received humane care in compli-
ance with the “Principles of Laboratory Animal Care” for-
mulated by the National Society for Medical Research and
the stipulations of the German Animal Protection Law in
its current version.
LPS-induced ARDS was performed as previously de-
scribed [15]. Briefly, specific pathogen free male Wistar
rats housed in standard conditions with food and water ad
libitum were anaesthetized by intraperitoneal (IP) injec-
tion of ketamine hydrochloride (50 mg/kg) and xylazine
(2 mg/kg). Anaesthesia was maintained with intravenous
ketamine via an infusion pump (Braun Perfusor Secura ft,
B. Braun Melsungen AG, Melsungen, Germany) at an ini-
tial rate of 20 mg/kg/h. The level of anaesthesia was
assessed by pinching the paw and tail throughout the ex-
periments. The femoral artery was cannulated with a poly-
ethylene catheter (PE-50, neoLab Heidelberg, Germany)
for multiple arterial blood collection. Subsequently, a cath-
eter system (AeroProbe, Trudell Medical International,
Ontario, Canada) was placed in the trachea for nebuliza-
tion of lipopolysaccharide (LPS) or saline solution. The
operating system (LABneb, Trudell Medical International,
Ontario, Canada) exerts a pressure of 60 psi and applies a
short puff synchronized with the respiration. The catheter
system was removed after application of the respective LPS
(serotype: E. Coli O55:B5, Sigma, Deisenhofen, Germany)
dose [of 25 μg/kg of body weight].
Following the experimental procedure, the animals were
observed with regard to weight changes by the examiner
of the group and independently thereof by the animal
keepers twelve, twenty-four, forty and seventy-two hours
after LPS- or LPS plus EPC-administration. At the final
stage after seventy-two hours, the animals were eutha-
nized under deep anaesthetic, and the lungs were exposed
for removal. The right-hand middle lobe was weighed
directly after the final stage and after twenty-four hours
in the cabinet drier to determine wet/dry-ratio (W/D ra-
tio), a correlate for quantification of pulmonary edema.
Remaining pulmonary lobes and organs were conserved in
paraffin. We will refer to the different animal groups in
Rafat et al. BMC Research Notes 2014, 7:613 Page 7 of 8
http://www.biomedcentral.com/1756-0500/7/613the rest of our manuscript as follows: control group = ani-
mals receiving only sodium chloride; non-treatment
group = animals with LPS-induced ARDS, which were not
administered BMDPC; treatment group = animals with
LPS-induced ARDS, which were administered BMDPC.
Isolation and administration of bone marrow-derived
progenitor cells
In order to isolate bone marrow-derived progenitor cells
(BMDPC), the femoral bone marrow of about eight-
weeks-old Wistar rats has been used; the rats have first
been narcotized with Isoflurane and then euthanized by
cervical dislocation. The cell cylinder was filtered through
a 40 μm filter, and the mononuclear cells were isolated by
density centrifugation. The vitality test of the cell suspen-
sion was carried out with trypan blue staining. BMDPC
were isolated from the bone marrow cell suspension by
positive selection for CD133 by microbeads associated with
monoclonal anti-CD133-antibodies (Miltenyi Biotech). For
the CD133-microbead column 2 × 108 bone marrow
mononuclear cells were used, and the magnetic column
was applied according to the manufacturer’s instructions.
Directly after LPS injection, the animals were administered
under anaesthesia via the tail vein either a 1x106 suspension
of CD133+-cells dissolved in 1 ml of sodium chloride 0.9%
or only 1 ml sodium chloride 0.9% for the control group.
Histopathologic evaluation
Lung biopsies were performed at the lower lobes (left
and right) in all animals, fixed with 4% non-buffered
formalin for 24 hours, parafinized and sectioned for
subsequent staining with hematoxylin and eosin, CD45
(Santa Cruz, Heidelberg, Germany), ICAM-1 (R&D Sys-
tems, Wiesbaden-Nordenstadt, Germany) and VCAM-
1/CD106 (BD Biosciences, Heidelberg, Germany) for
histological assessment using light microscopy.
Endothelial Outgrowth Cell (EOC) Assay
BMDPC were isolated from the bone marrow cell suspen-
sion by positive selection for CD133 by microbeads associ-
ated with monoclonal anti-CD133-antibodies as described
above. Cells were suspended in growth medium (Medium
207), placed on fibronectin-coated dishes and incubated
for 3 weeks as described earlier [36]. The medium was
replenished every 3 days. Staining with CD133-FITC
(Abcam, Cambridge, UK) and CD31-FITC (BD Biosci-
ences, Heidelberg, Germany) was performed to assess
endothelial character via phase contrast microscopy.
BMDPC homing assay
BMDPC were isolated from the bone marrow cell suspen-
sion by positive selection for CD133 by microbeads associ-
ated with monoclonal anti-CD133-antibodies as described
above. Cells were stained with DiI (Life TechnologiesGmbH, Darmstadt, Germany) and administered directly
after LPS injection into the animals. After forty-eight hours
the animals were sacrificed and their lung tissue analysed.
Enzyme-linked immune-sorbent assay (ELISA)
The concentrations of vascular endothelial growth factor
(VEGF) were assessed in bronchoalveolar lavage (BAL)
using enzyme-linked immunosorbent assay kits (R&D
Systems, Wiesbaden-Nordenstadt, Germany) in triplicate
samples. Enzyme-linked immunosorbent assays were per-
formed according to the manufacturer’s instructions.
Statistical methods
The statistical comparisons were carried out by means
of the student t-test. We considered p < 0.05 to be statis-
tically significant.
Abbreviations
ALI: Acute lung injury; ARDS: Acute respiratory distress syndrome;
BMDPC: Bone marrow-derived progenitor cells; ELISA: Enzyme-linked
immunosorbent assay; EPC: Endothelial progenitor cells; ICAM-1: Intercellular
adhesion molecule-1; LPS: Lipopolysaccharide; VCAM-1: Vascular cell
adhesion molecule-1; VEGF: Vascular endothelial growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NR made substantial contributions to conception and design of the study,
carried out the study, performed animal experiments and collected all data,
performed the statistical analysis, and drafted the manuscript. GK made
substantial contributions to conception and design of the study, carried out
the study, performed animal experiments and collected data. CB made
substantial contributions to conception and design of the study, carried out the
study and drafted the manuscript. BT, BY and GB made substantial contributions
to conception and design and supervised the conduct of the study, and writing
of the article. All authors read and approved the final manuscript.
Acknowledgement
We thank Jutta Schulte for her skillful technical assistance and Krista Rafat for her
editing assistance in the preparation of the manuscript. This study was supported
by a research grant from the German Research Foundation (Deutsche
Forschungsgemeinschaft). N.R. & C.B. were supported by a research scholarship
from the Postdoc-Program of the University of Heidelberg. We also acknowledge
financial support by Deutsche Forschungsgemeinschaft and Ruprecht-Karls-
Universität Heidelberg within the funding programme Open Access Publishing.
Author details
1Department of Pediatrics I, University Children’s Hospital Heidelberg,
University of Heidelberg, Heidelberg, Germany. 2Clinic for Anaesthesiology
and Critical Care Medicine, Alfried-Krupp-Krankenhaus, Essen, Germany.
3Department of Radiology, Minimally Invasive Therapies and Nuclear
Medicine, SLK Kliniken Heilbronn GmbH, Heilbronn, Germany. 4Division of
Functional Genome Analysis, German Cancer Research Center (DKFZ),
Heidelberg, Germany. 5Department of Medicine V, Mannheim University
Medical Center, University of Heidelberg, Heidelberg, Germany. 6Department
for Anaesthesiology and Intensive Care Medicine, Dr. Horst-Schmidt Clinic,
Wiesbaden, Germany.
Received: 4 June 2014 Accepted: 29 August 2014
Published: 8 September 2014
References
1. Bhadade RR, de Souza RA, Harde MJ, Khot A: Clinical characteristics and
outcomes of patients with acute lung injury and ARDS. J Postgrad Med
2011, 57:286–290.
Rafat et al. BMC Research Notes 2014, 7:613 Page 8 of 8
http://www.biomedcentral.com/1756-0500/7/6132. Mutunga M, Fulton B, Bullock R, Batchelor A, Gascoigne A, Gillespie JI,
Baudouin SV: Circulating endothelial cells in patients with septic shock.
Am J RespirCrit Care Med 2001, 163:195–200.
3. Orfanos SE, Mavrommati I, Korovesi I, Roussos C: Pulmonary endothelium
in acute lung injury: from basic science to the critically ill. Intensive Care
Med 2004, 30:1702–1714.
4. Ware L, Matthay M: The acute respiratory distress syndrome. N Engl J Med
2000, 342:1334–1349.
5. Ware LB: Pathophysiology of acute lung injury and the acute respiratory
distress syndrome. Semin Respir Crit Care Med 2006, 27:337–349.
6. Meade MO, Cook DJ, Guyatt GH, Slutsky AS, Arabi YM, Cooper DJ, Davies
AR, Hand LE, Zhou Q, Thabane L, Austin P, Lapinsky S, Baxter A, Russell J,
Skrobik Y, Ronco JJ, Stewart TE: Ventilation strategy using low tidal
volumes, recruitment maneuvers, and high positive end-expiratory
pressure for acute lung injury and acute respiratory distress syndrome: a
randomized controlled trial. JAMA 2008, 299:637–645.
7. Mercat A, Richard J-CM, Vielle B, Jaber S, Osman D, Diehl J-L, Lefrant J-Y, Prat
G, Richecoeur J, Nieszkowska A, Gervais C, Baudot J, Bouadma L, Brochard L:
Positive end-expiratory pressure setting in adults with acute lung injury
and acute respiratory distress syndrome: a randomized controlled trial.
JAMA 2008, 299:646–655.
8. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA: Intrapulmonary
delivery of bone marrow-derived mesenchymal stem cells improves
survival and attenuates endotoxin-induced acute lung injury in mice.
J Immunol 2007, 179:1855–1863.
9. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA: Allogeneic human
mesenchymal stem cells for treatment of E. coli endotoxin-induced
acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci
U S A 2009, 106:16357–16362.
10. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA:
Therapeutic effects of human mesenchymal stem cells in ex vivo human
lungs injured with live bacteria. Am J Respir Crit Care Med 2013, 187:751–760.
11. Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, Iyer S, Rojas M: Prevention of
endotoxin-induced systemic response by bone marrow-derived mesenchymal
stem cells in mice. AJP - Lung Cell Mol Physiol 2007, 293:L131–L141.
12. Rafat N, Hanusch C, Brinkkoetter PT, Schulte J, Brade J, Zijlstra JG, van der
Woude FJ, van Ackern K, Yard BA, Beck GC: Increased circulating
endothelial progenitor cells in septic patients: correlation with survival.
Crit Care Med 2007, 35:1677–1684.
13. Rafat N, Tönshoff B, Bierhaus A, Beck GC: Endothelial progenitor cells in
regeneration after acute lung injury: do they play a role? Am J Respir Cell
Mol Biol 2013, 48:399–405.
14. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T,
Witzenbichler B, Schatteman G, Isner JM: Isolation of putative progenitor
endothelial cells for angiogenesis. Science 1997, 275:964–967.
15. Rafat N, Kowanetz G, Krebs J, Tsagogiorgas C, Betzen C, Ghezel-Ahmadi V,
Yard B, Beck G, Dacho C: Therapeutic Effects of Bone Marrow-derived
Progenitor Cells in Lipopolysaccharide-induced Acute Respiratory
Distress Syndrome. J Pulm Respir Med 2014, 4:2.
16. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T,
Isner JM, Asahara T: Transplantation of ex vivo expanded endothelial
progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA
2000, 97:3422–3427.
17. Burnham EL, Taylor WR, Quyyumi AA, Rojas M, Brigham KL, Moss M:
Increased circulating endothelial progenitor cells are associated with
survival in acute lung injury. Am J RespirCrit Care Med 2005, 172:854–860.
18. Sala E, Villena C, Balaguer C, Ríos A, Fernández-Palomeque C, Cosío BG,
García J, Noguera A, Agustí A: Abnormal levels of circulating endothelial
progenitor cells during exacerbations of COPD. Lung 2010, 188:331–338.
19. Yamada M, Kubo H, Kobayashi S, Ishizawa K, Numasaki M, Ueda S, Suzuki T,
Sasaki H: Bone marrow-derived progenitor cells are important for lung
repair after lipopolysaccharide-induced lung injury. J Immunol 2004,
172:1266–1272.
20. Lam CF, Liu YC, Hsu JK, Yeh PA, Su TY, Huang CC, Lin MW, Wu PC, Chang
PJ, Tsai YC: Autologous transplantation of endothelial progenitor cells
attenuates acute lung injury in rabbits. Anesthesiology 2008, 108:392–401.
21. Lam CF, Roan JN, Lee CH, Chang PJ, Huang CC, Liu YC, Jiang MJ, Tsai YC:
Transplantation of Endothelial Progenitor Cells Improves Pulmonary
Endothelial Function and Gas Exchange in Rabbits with Endotoxin-
Induced Acute Lung Injury. Anesth Analg 2011, 112:620–627.22. Kähler CM, Wechselberger J, Hilbe W, Gschwendtner A, Colleselli D,
Niederegger H, Boneberg E-M, Spizzo G, Wendel A, Gunsilius E, Patsch JR,
Hamacher J: Peripheral infusion of rat bone marrow derived endothelial
progenitor cells leads to homing in acute lung injury. Respir Res 2007, 8:50.
23. Mao M, Wang SN, Lv XJ, Wang Y, Xu JC: Intravenous delivery of bone marrow-
derived endothelial progenitor cells improves survival and attenuates
lipopolysaccharide-induced lung injury in rats 19. Shock 2010, 34:196–204.
24. Wary KK, Vogel SM, Garrean S, Zhao YD, Malik AB: Requirement of alpha(4)
beta(1) and alpha(5)beta(1) integrin expression in bone-marrow-derived
progenitor cells in preventing endotoxin-induced lung vascular injury
and edema in mice 1. Stem Cells 2009, 27:3112–3120.
25. Gao X, Chen W, Liang Z, Chen L: Autotransplantation of circulating
endothelial progenitor cells protects against lipopolysaccharide-induced
acute lung injury in rabbit. Int Immunopharmacol 2011, 11:1584–1590.
26. Rehman J, Li J, Orschell CM, March KL: Peripheral blood “endothelial
progenitor cells” are derived from monocyte/macrophages and secrete
angiogenic growth factors. Circulation 2003, 107:1164–1169.
27. Rojas M, Cárdenes N, Kocyildirim E, Tedrow JR, Cáceres E, Deans R, Ting A,
Bermúdez C: Human adult bone marrow-derived stem cells decrease
severity of lipopolysaccharide-induced acute respiratory distress
syndrome in sheep. Stem Cell Res Ther 2014, 5:42.
28. Fan H, Goodwin AJ, Chang E, Zingarelli B, Borg K, Guan S, Halushka PV,
Cook JA: Endothelial progenitor cells and a SDF-1α analogue
synergistically improve survival in sepsis. Am J Respir Crit Care Med
2014, [Epub ahead of print].
29. Ziegelhoeffer T, Fernandez B, Kostin S, Heil M, Voswinckel R, Helisch A,
Schaper W: Bone marrow-derived cells do not incorporate into the adult
growing vasculature. Circ Res 2004, 94:230–238.
30. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM,
Dimmeler S: Soluble factors released by endothelial progenitor cells
promote migration of endothelial cells and cardiac resident progenitor
cells. J Mol Cell Cardiol 2005, 39:733–742.
31. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin
DJ, Witte L, Moore MA, Rafii S: Expression of VEGFR-2 and AC133 by
circulating human CD34(+) cells identifies a population of functional
endothelial precursors. Blood 2000, 95:952–958.
32. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel
H, Rafii S: Vascular trauma induces rapid but transient mobilization of
VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 2001, 88:167–174.
33. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J,
Homma S, Edwards NM, Itescu S: Neovascularization of ischemic
myocardium by human bone-marrow-derived angioblasts prevents
cardiomyocyte apoptosis, reduces remodeling and improves cardiac
function. Nat Med 2001, 7:430–436.
34. Achilli F, Malafronte C, Lenatti L, Gentile F, Dadone V, Gibelli G, Maggiolini S,
Squadroni L, Di Leo C, Burba I, Pesce M, Mircoli L, Capogrossi MC, Di Lelio
A, Camisasca P, Morabito A, Colombo G, Pompilio G: Granulocyte
colony-stimulating factor attenuates left ventricular remodelling after
acute anterior STEMI: results of the single-blind, randomized,
placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial
Infarction (STEM-AMI) Trial. Eur J Heart Fail 2010, 12:1111–1121.
35. Achilli F, Malafronte C, Maggiolini S, Lenatti L, Squadroni L, Gibelli G,
Capogrossi MC, Dadone V, Gentile F, Bassetti B, Di Gennaro F, Camisasca P,
Calchera I, Valagussa L, Colombo GI, Pompilio G: G-CSF treatment for
STEMI: final 3-year follow-up of the randomised placebo-controlled
STEM-AMI trial. Heart 2014, 100:574–581.
36. Zeisberger SM, Zoller S, Riegel M, Chen S, Krenning G, Harmsen MC, Sachinidis A,
Zisch AH: Optimization of the culturing conditions of human umbilical cord
blood-derived endothelial colony-forming cells under xeno-free conditions
applying a transcriptomic approach. Genes Cells 2010, 15:671–687.
doi:10.1186/1756-0500-7-613
Cite this article as: Rafat et al.: Bone marrow-derived progenitor cells
attenuate inflammation in lipopolysaccharide-induced acute
respiratory distress syndrome. BMC Research Notes 2014 7:613.
